血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系

Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib

目的 评估血清KL-6水平对安罗替尼治疗非小细胞肺癌患者预后的影响。方法 选取2020年1月-12月桂林市人民医院收治的80例非小细胞肺癌(NSCLC)患者为研究对象,根据是否接受安罗替尼治疗分为NSCLC组和安罗替尼+NSCLC组,各40例。NSCLC组接受常规治疗,安罗替尼+NSCLC组在常规治疗基础上联合安罗替尼口服治疗。比较两组血清KL-6水平,分析安罗替尼+NSCLC组血清KL-6水平与临床病理特征、生存时间的关系,Kaplan-Meier曲线和多变量Cox回归模型确定安罗替尼+NSCLC组患者预后不良的影响因素。结果 安罗替尼+NSCLC组血清KL-6水平低于NSCLC组,差异有统计学意义(P<0.05);不同年龄、性别、组织学类型、肿瘤分化程度的安罗替尼+NSCLC组患者血清KL-6水平比较,差异无统计学意义(P>0.05);不同病理分期和转移部位数的安罗替尼+NSCLC组患者血清KL-6水平比较,差异有统计学意义(P<0.05);高KL-6水平的安罗替尼+NSCLC组患者中位生存期、总生存时间少于低KL-6水平的患者,差异有统计学意义(P<0.05);多变量Cox回归模型显示,KL-6水平是影响安罗替尼+NSCLC组患者预后不良的独立因素。结论 血清KL-6水平可作为安罗替尼治疗的NSCLC患者预后的生物标志物。

Objective To evaluate the effect of serum KL-6 level on the prognosis of patients with non-small cell lung cancer treated with anrotinib.Methods A total of 80 patients with non-small cell lung cancer(NSCLC) admitted to Guilin People’s Hospital from January to December 2020 were selected as the research objects.They were divided into NSCLC group and Anrotinib +NSCLC group according to whether they received anrotinib treatment,with 40 cases in each group.The NSCLC group received routine treatment,and the anrotinib +NSCLC group received oral anrotinib treatment on the basis of routine treatment.The serum KL-6 levels of the two groups were compared,and the relationship between the serum KL-6level of the anrotinib+NSCLC group and the clinical pathological characteristics and survival time was analyzed.Kaplan-Meier curve and multivariate Cox regression model were used to determine the influencing factors of poor prognosis in patients with anrotinib+NSCLC group.Results The serum KL-6 level in the anrotini+NSCLC group was lower than that in the NSCLC group,and the difference was statistically significant( P<0.05).There was no significant difference in the serum KL-6 level between the patients with different ages,genders,histological types,and tumor differentiation degrees in the anrotini+NSCLC group(P>0.05).There was statistically significant difference in serum KL-6 level of anlotinib+NSCLC patients with different pathological stages and number of metastasis sites(P<0.05).The median survival and overall survival time of patients with high KL-6 level in anlotinib +NSCLC group were lower than those with low KL-6 level,the differences were statistically significant( P <0.05).Multivariate Cox regression model showed that KL-6 level was an independent factor influencing poor prognosis of anlotinib+NSCLC patients.Conclusion Serum KL-6level can be used as a biomarker for prognosis of NSCLC patients treated with anlotinib.